The best peptides for longevity, judged by evidence, are not the ones marketed as anti-aging. No peptide has been shown to extend human lifespan. The closest evidence comes from GLP-1 drugs: in the 17,604-person SELECT trial, semaglutide cut death from any cause by 19% in people with obesity and heart disease.[3] Epitalon, MOTS-c, humanin and GHK-Cu, the peptides most often sold for longevity, have animal or cell data but no human lifespan data.[5][11]
“Longevity” claims usually rest on lab markers such as telomere length, mitochondrial function or gene activity, or on lifespan in worms and mice. None of those reliably predicts longer human life. This guide grades each peptide on what was actually measured. For related compounds, see the longevity peptides hub.
Best peptides for longevity: evidence at a glance
| Peptide or approach | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Physical activity | Human studies (observational) | Most active quarter: about 73% lower death risk than least active[1] | Not a drug | — |
| Semaglutide and other GLP-1 drugs | Human RCTs | 19% fewer deaths in SELECT; 12% fewer across diabetes trials[3][4] | Approved for obesity, diabetes and heart risk, not aging | Semaglutide |
| SS-31 (elamipretide) | FDA-approved for a rare disease only | Raised muscle energy output briefly in older adults; no aging outcomes[14] | Accelerated approval for Barth syndrome, 2025[13] | SS-31 |
| Epitalon | Small human studies | Telomerase in cells; no average lifespan gain in mice[6][7] | Not approved | Epitalon |
| MOTS-c | Animal or lab only | Better physical capacity in old mice[10] | Not approved | MOTS-c |
| Humanin | Animal or lab only | Longer life in worms; healthier middle-aged mice[12] | Not approved | Humanin |
| GHK-Cu | Animal or lab only (for aging) | Skin and wound effects; gene-activity claims from lab data[15] | Cosmetic ingredient; not approved as a drug | GHK-Cu |
| FOXO4-DRI | Animal or lab only | Cleared aging cells and improved fitness in mice[16] | Not approved | FOXO4-DRI |
What works: activity and treating disease
The habits with the strongest links to long life are not peptides. In a pooled analysis of 36,383 adults wearing activity trackers, the most active quarter had a 73% lower risk of dying during about six years of follow-up than the least active quarter, and any activity, even light, was linked to lower risk. These are observational studies, so they show association rather than proof.[1]
GLP-1 drugs: the best human mortality data
GLP-1 drugs such as semaglutide, liraglutide and tirzepatide are peptides, and they have the only randomized mortality data of any peptide in this guide.
- SELECT: 17,604 adults 45 and older with overweight or obesity and heart disease, but no diabetes, took semaglutide 2.4 mg weekly or placebo. Heart attacks, strokes and cardiovascular deaths fell 20%.[2] A follow-up analysis found death from any cause was 19% lower, driven by fewer cardiovascular and non-cardiovascular deaths, especially from infection.[3]
- Diabetes trials: a 2025 meta-analysis of 10 trials and 71,351 people with type 2 diabetes found long-acting GLP-1 drugs lowered all-cause death by 12%.[4]
These were people with disease, followed for a few years. Nobody has tested whether GLP-1 drugs extend life in healthy people, and they cause gut side effects and muscle loss along with fat loss. Our GLP-1 heart outcomes guide has the details.
The anti-aging peptides, graded
Epitalon
Epitalon is a four-amino-acid peptide based on a pineal gland extract. In human fetal cells it switched on telomerase and lengthened telomeres.[6] In female mice given monthly injections for life, average lifespan did not change, though the longest-lived 10% lived about 13% longer.[7] A Russian study by its developers reported lower death rates in 266 older adults given pineal and thymus extracts, but it has not been independently confirmed.[8] FDA found no clinical studies of epitalon for insomnia, the use it reviewed, yet its advisers voted to recommend it for compounding in July 2026.[5][17] See our epitalon vs TA-65 comparison.
MOTS-c and humanin
MOTS-c and humanin are small peptides encoded in mitochondrial DNA. MOTS-c protected mice from diet-induced obesity and insulin resistance,[9] and late-life treatment improved physical capacity in old mice.[10] FDA found no human exposure data or animal toxicity studies for MOTS-c.[11] Humanin extended lifespan in worms and improved health markers in middle-aged mice, and children of centenarians had higher levels.[12] Neither has been tested as a treatment in a published human trial. Our mitochondrial peptides review covers both.
SS-31 (elamipretide)
SS-31 binds a fat in the inner mitochondrial membrane. FDA granted it accelerated approval in September 2025 as Forzinity for Barth syndrome, a rare genetic disease.[13] In 39 healthy older adults, a single infusion raised muscle energy output right afterward, but the effect was gone a week later and fatigue resistance did not change.[14]
GHK-Cu and FOXO4-DRI
GHK-Cu is a copper peptide found in blood that declines with age. It aids wound healing and skin repair in lab and animal work, and claims that it “resets” thousands of genes come from lab gene-expression data, not human aging outcomes.[15] FOXO4-DRI is a designed peptide that triggered death of aging “senescent” cells and restored fur, fitness and kidney function in old mice.[16] It has no published human trials. See our GHK-Cu research review for the skin evidence.
Safety and the telomerase question
Turning on telomerase sounds appealing, but cancer cells use telomerase to keep dividing, so long-term effects of telomerase activators in people are a real unknown. FDA has also raised concerns that peptides sold online may contain impurities or cause immune reactions, and for MOTS-c it found no toxicity studies at all.[11]
Questions for your clinician
- Which proven steps, such as activity, blood pressure, cholesterol and weight management, would most improve my health span?
- Do I have a condition, like obesity with heart disease, where a GLP-1 drug has outcome data?
- What are the risks of an unapproved peptide given my cancer and family history?
- How would we measure whether anything I take is helping?
The bottom line
The best peptides for longevity, by evidence, are GLP-1 drugs in people who have the diseases they treat, where trials show fewer deaths. The peptides marketed for anti-aging, including epitalon, MOTS-c, humanin, GHK-Cu and FOXO4-DRI, have promising animal or lab results but no human lifespan data. Related reading: Khavinson peptide bioregulators and peptides vs exosomes.
This is general information, not medical advice.
